Potential for pantoprazole use in the therapy of gastroesophageal reflux disease
Erosive esophagitis is one of the most severe clinical forms of gastroesophageal reflux disease (GERD), a lifelong health condition, which occurs as a result of gastric juice reflux into the esophagus. More than 40% of the adult population has GERD symptoms, expressed in varying degrees and the registered at least 2 times a week. GERD-induced esophagus damage can cause more serious complications, such as stricture, bleeding, and the precancer formation - Barrett's esophagus. In GERD treatment the drugs of choice are the modern acid production blockers (proton pump inhibitors, PPI). The analysis of the literature data for optimal choice of PPIs for the GERD treatment highlights the advantages of pantoprazole. We consider the metabolism characteristics of this drug administration in standard doses in comparison with other PPIs.

Keywords: drug-drug interactions, pantoprazole, proton pump inhibitors, gastroesophageal reflux disease, cytochrome P450